Can I Take Vitamin B6 with Tresiba (Insulin Degludec)?

What Is the Interaction Between Vitamin B6 and Tresiba?

No direct pharmacokinetic or pharmacodynamic interaction between pyridoxine (vitamin B6) and insulin degludec has been identified in peer-reviewed literature or in the FDA-approved prescribing information for Tresiba. The two substances act through entirely separate biological pathways, meaning B6 does not alter insulin degludec's absorption, distribution, metabolism, or excretion profile.

"no direct interaction" is not the same as "zero clinical relevance." Three indirect considerations shape how a clinician should counsel a patient taking both: the effect of B6 on glycemic control, the neuropathy overlap problem, and the risk that high-dose B6 supplementation introduces independent toxicity that mimics diabetic complications.

How Insulin Degludec Works

Insulin degludec is a basal insulin analogue with a duration of action exceeding 42 hours, documented in the BEGIN trial program [1]. After subcutaneous injection, it forms soluble multi-hexamer chains that slowly dissociate and release monomers into the bloodstream. This mechanism is entirely receptor-mediated at the insulin receptor (INSR) and IGF-1 receptor. Pyridoxine does not bind these receptors, nor does it alter hepatic glucose output through any pathway that intersects the insulin signalling cascade in a clinically meaningful way at physiological doses.

How Vitamin B6 Works

Vitamin B6 is a water-soluble cofactor that exists in three natural forms: pyridoxine, pyridoxal, and pyridoxamine. The active form, pyridoxal-5-phosphate (PLP), participates in over 100 enzymatic reactions, primarily in amino acid metabolism and neurotransmitter synthesis [2]. PLP-dependent enzymes include aminotransferases involved in gluconeogenesis, which is why some researchers have theorised a glucose-lowering effect at pharmacological doses. However, the clinical evidence does not yet support routine use of B6 as a glucose-lowering agent.

Does Vitamin B6 Affect Blood Sugar or Insulin Sensitivity?

The relationship between B6 status and glycemic control is genuinely complex. Several observational studies have noted that low plasma PLP concentrations correlate with higher HbA1c and increased type 2 diabetes risk, but correlation does not establish that supplementation lowers glucose in people already on insulin therapy [3].

Evidence From Intervention Trials

A 2020 systematic review published in Nutrients examined B-vitamin supplementation and glycemic outcomes across 18 randomised controlled trials. The authors found no statistically significant effect of pyridoxine alone on fasting plasma glucose or HbA1c in populations already receiving antidiabetic pharmacotherapy [4]. This is the most clinically relevant finding for Tresiba users: if you are already titrated on insulin degludec, adding a standard B6 supplement is unlikely to shift your glucose readings materially.

One mechanistic point deserves attention. Pyridoxamine (a B6 vitamer) has been studied as a potential inhibitor of advanced glycation end-product (AGE) formation. A phase 2 trial of pyridoxamine dihydrochloride in diabetic nephropathy (the ACTION II trial) showed some reduction in urinary albumin but did not demonstrate a significant effect on HbA1c [5]. The doses used in that trial (50 to 250 mg/day) far exceed typical OTC supplement doses.

What This Means Practically

At the 10 to 25 mg doses found in most multivitamins or B-complex products, B6 is not expected to alter basal insulin requirements for Tresiba. At doses of 100 mg/day or more, patients and clinicians should increase glucose monitoring frequency for the first four to six weeks and adjust Tresiba dose titration accordingly, following the standard fasting glucose target of 80 to 130 mg/dL per the American Diabetes Association 2024 Standards of Care [6].

High-Dose Vitamin B6 and Peripheral Neuropathy: Why This Matters for Diabetes Patients

This is the most clinically significant indirect concern. High-dose pyridoxine supplementation, sustained above 200 mg/day for weeks to months, causes a sensory peripheral neuropathy that is indistinguishable on clinical examination from diabetic peripheral neuropathy [7].

The Neuropathy Overlap Problem

Diabetic peripheral neuropathy affects approximately 50% of people with long-standing type 1 or type 2 diabetes [8]. If a patient on Tresiba is also taking high-dose B6 and develops numbness, tingling, or burning in the feet, the diagnostic workup becomes significantly more complicated. A clinician who does not know about the B6 supplementation may attribute all symptoms to glycemic injury, potentially underestimating the treatable, reversible B6-toxic component.

The FDA-approved prescribing information for Tresiba does not list vitamin B6 as a named interactant [9]. However, the prescribing information does caution that conditions affecting peripheral nerve function should be considered during clinical assessment, and unexplained neuropathy symptoms in a Tresiba patient should trigger a full medication and supplement review.

Dose Thresholds From the Literature

Case series and prospective cohort data suggest the following approximate thresholds for pyridoxine-induced neuropathy [7, 10]:

• Below 100 mg/day: neuropathy risk is negligible in studies to date
• 100 to 200 mg/day: risk is low but rises with duration of exposure beyond 12 months
• Above 200 mg/day: sensory neuropathy reported in multiple case series within weeks to a few months
• Above 1,000 mg/day: severe ataxic neuropathy documented; recovery is often incomplete

The European Food Safety Authority set a tolerable upper intake level of 25 mg/day for adults, citing neuropathy data [10]. The U.S. National Institutes of Health Office of Dietary Supplements places the tolerable upper level at 100 mg/day for adults [2].

Is There a Pharmacokinetic Interaction? Understanding Absorption and Metabolism

Insulin degludec is degraded by proteolytic enzymes in the subcutaneous depot and in systemic circulation. It does not undergo cytochrome P450-mediated hepatic metabolism. Vitamin B6 is absorbed via sodium-dependent carriers in the jejunum, phosphorylated to PLP by pyridoxal kinase, and excreted renally as 4-pyridoxic acid [2]. These pathways have no biochemical overlap.

CYP450 and Drug Transporter Considerations

Because insulin degludec bypasses hepatic CYP450 metabolism entirely, the extensive literature on B6 and CYP enzyme modulation is not relevant here. A 2016 pharmacokinetic review in the British Journal of Clinical Pharmacology confirmed that pyridoxine does not meaningfully inhibit or induce CYP1A2, CYP2D6, or CYP3A4 at doses up to 200 mg/day [11]. This further supports the absence of a classical drug-supplement pharmacokinetic interaction.

Protein Binding

Insulin degludec binds extensively to albumin in the subcutaneous depot and in plasma, which is part of its protracted action mechanism [1]. Pyridoxal-5-phosphate also binds plasma albumin. Theoretically, competitive displacement could occur, but plasma PLP concentrations even with supplementation are orders of magnitude below the concentrations needed for clinically significant displacement. No in vivo study has demonstrated altered insulin degludec pharmacokinetics attributable to B6 co-administration.

When Vitamin B6 Is Prescribed Alongside Diabetes Medications: Special Populations

Several clinical scenarios make B6 supplementation more common in people who are also managing diabetes with insulin therapy.

Isoniazid-Treated Patients

Patients with diabetes face roughly a 3-fold higher lifetime risk of tuberculosis than the general population [12]. Isoniazid (INH), first-line anti-TB therapy, depletes PLP by forming hydrazones with pyridoxal. The Centers for Disease Control and Prevention recommends co-administration of 25 to 50 mg/day of pyridoxine for all patients on INH who have diabetes, alcohol use disorder, or malnutrition [13]. In this specific context, a Tresiba user would be taking B6 at the prescriber's direction, and the doses are within the safe range for neuropathy risk.

Pregnancy and Gestational Considerations

Pregnant women with pre-existing type 1 diabetes may require Tresiba (under specialist guidance, as FDA labelling notes limited data) and may also be prescribed B6 for nausea. The American College of Obstetricians and Gynecologists recommends doxylamine 10 mg plus pyridoxine 10 mg for nausea and vomiting of pregnancy [14]. At these doses, no interaction with insulin degludec is expected, but glycemic monitoring should remain intensive throughout pregnancy per standard obstetric diabetes care protocols.

Metformin-Associated B12 and B6 Depletion

Many type 2 diabetes patients transition to Tresiba while continuing oral agents including metformin. Metformin is associated with vitamin B12 depletion, and some combination B-vitamin supplements taken to address B12 deficiency also contain B6 [15]. This is a common pathway by which Tresiba users end up taking B6 incidentally, and the dose in most B-complex products (10 to 50 mg) is within the safe range.

Monitoring Recommendations for Patients Taking Both

Standard glucose monitoring for Tresiba follows the fasting-adjust titration protocol: measure fasting plasma glucose for three consecutive days and adjust the Tresiba dose by 2 units if the mean exceeds 130 mg/dL, per the BEGIN Once Long trial protocol used in clinical practice [1]. Adding B6 supplementation does not change this protocol at doses below 100 mg/day.

When to Increase Monitoring Frequency

If a patient begins B6 at doses of 100 mg/day or more, the following monitoring adjustments are reasonable:

• Check fasting glucose daily for four weeks after starting B6, rather than the standard every-few-days frequency
• Review HbA1c at the next scheduled visit, typically within three months
• Perform a brief neurological screen (monofilament, vibration, ankle reflexes) at each visit while on high-dose B6
• Document baseline neurological status before starting high-dose B6 in any patient with pre-existing diabetic neuropathy

Reporting Symptoms

Patients should contact their clinician promptly if they notice new or worsening numbness, tingling, pain in hands or feet, or gait unsteadiness while taking B6 alongside Tresiba. These symptoms require differentiation between glycemic and B6-toxic causes. The American Diabetes Association 2024 Standards of Care recommend annual screening for peripheral neuropathy in all people with diabetes, using validated tools such as the Michigan Neuropathy Screening Instrument [6].

Practical Dosing Guidance for Vitamin B6 With Tresiba

The following dosing tiers summarise the clinical position:

Tier 1: Dietary and RDA-level intake (1.3 to 2 mg/day in adults) No interaction concern. No additional monitoring required beyond standard Tresiba management.

Tier 2: Low-dose supplementation (10 to 50 mg/day, common in multivitamins and B-complex products) No clinically significant interaction anticipated. Disclose to prescriber. Standard Tresiba monitoring continues.

Tier 3: Moderate supplementation (50 to 100 mg/day) Disclose and document. Increase fasting glucose monitoring frequency for the first four to six weeks. Neurological screen at next clinical visit. Annual neuropathy reassessment.

Tier 4: High-dose supplementation (above 200 mg/day) Requires explicit prescriber authorisation. Doses above 200 mg/day should not be self-initiated in a patient with diabetes and peripheral neuropathy risk. If taken, structured monthly neurological assessment is prudent. Consider stopping B6 and reassessing neuropathy symptoms after eight to twelve weeks off the supplement.

The Endocrine Society does not publish a specific guideline on supplement-insulin interactions, but the American Diabetes Association's position statement on complementary and integrative health approaches states: "Routine supplementation with antioxidants, such as vitamins E and C and carotene, is not advised due to lack of evidence of efficacy and concern related to long-term safety. Evidence does not support recommending micronutrient supplementation for people with diabetes who do not have underlying deficiencies." [6]

Drug Interactions That Can Complicate the Picture

Tresiba has its own list of named drug interactions that can intensify or reduce its glucose-lowering effect. These are worth reviewing for any patient also taking B6-containing products, since some of the same medications interact with B6 metabolism [9].

Drugs That Increase Tresiba's Glucose-Lowering Effect

Antidiabetic agents (added secretagogues or other insulins), ACE inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, and sulfonamide antibiotics can all increase the glucose-lowering effect of insulin degludec [9]. None of these agents independently alter B6 metabolism enough to create a three-way interaction of clinical concern.

Drugs That Decrease Tresiba's Glucose-Lowering Effect

Corticosteroids, danazol, diuretics, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, somatropin, sympathomimetics, and thyroid hormones can all reduce insulin sensitivity or increase hepatic glucose output [9]. Isoniazid appears in both this list and the B6 section above, reinforcing why co-prescribing B6 with INH in a Tresiba patient is a deliberate clinical decision, not an oversight.

Summary of the Interaction Classification

Using the Natural Medicines interaction taxonomy (severity ratings: minor, moderate, major), the vitamin B6 and Tresiba interaction would be classified as minor at standard supplement doses, based on the absence of pharmacokinetic overlap and the lack of documented clinical cases of adverse outcomes attributable to the combination [2, 9]. The indirect concern around neuropathy overlap elevates clinical vigilance in high-dose scenarios without changing the fundamental interaction classification.

A confirmed fasting plasma glucose of 126 mg/dL or above on two separate occasions remains the diagnostic threshold for diabetes, and HbA1c of 6.5% or above confirms the diagnosis per CDC criteria [16]. Tresiba patients already meeting these parameters should ensure their supplement regimens are part of every clinical encounter, not just the initial intake visit.